PathWhiz ID | Pathway | Meta Data |
---|---|---|
PW144625View Pathway |
drug action
Ritonavir Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:03 Last Updated: October 07, 2023 at 14:03 |
PW126595View Pathway |
drug action
RivaroxabanHomo sapiens
Rivaroxaban is a factor Xa inhibitor used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). May also be used as thrombosis prophylaxis in specific situations. Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor.
Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment.
Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process.
|
Creator: Karxena Harford Created On: January 19, 2022 at 01:23 Last Updated: January 19, 2022 at 01:23 |
PW128037View Pathway |
drug action
Rivaroxaban Action PathwayHomo sapiens
Rivaroxaban is an anticoagulant that inhibits coagulation factor X, typically used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). Rivaroxaban is indicated for patients at high risk of DVT, PE and any other recurrent thrombotic events. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Rivaroxaban competitively inhibits free and clot-bound factor X. Coagulation factor X makes up a part of the prothrombinase complex that is responsible for the conversion of prothrombin to thrombin. Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which creates the loose meshwork that eventually forms into a blood clot. Patients should avoid herbs and supplements with anticoagulant activity such as garlic, ginger, bilberry, danshen, piracetam and ginkgo biloba. In addition, St. John's Wort should also be avoided as it will decrease blood concentration levels of rivaroxaban.
|
Creator: Selena Created On: July 06, 2023 at 10:17 Last Updated: July 06, 2023 at 10:17 |
PW132486View Pathway |
Rivaroxaban Drug MetabolismHomo sapiens
Rivaroxaban is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Rivaroxaban passes through the liver and is then excreted from the body mainly through the kidney.
|
Creator: Ray Kruger Created On: September 21, 2023 at 22:02 Last Updated: September 21, 2023 at 22:02 |
PW145688View Pathway |
drug action
Rivaroxaban Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 16:23 Last Updated: October 07, 2023 at 16:23 |
PW128009View Pathway |
drug action
Rivastigmine Action PathwayHomo sapiens
Rivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's. The drug reversible binds to and inhibits acetylcholinesterase and cholinesterase which stops the breakdown of acetylcholine which increases the concentration in the synaptic cleft. It is metabolized by the enzymes it inhibits and forms the metabolite NAP226-90.
|
Creator: Selena Created On: June 29, 2023 at 09:31 Last Updated: June 29, 2023 at 09:31 |
PW128292View Pathway |
drug action
Rivastigmine Action Pathway (new)Homo sapiens
Rivastigmine is a cholinesterase inhibitor used in the treatment of symptoms of dementia in Alzheimer's and Parkinson's. The drug reversible binds to and inhibits acetylcholinesterase and cholinesterase which stops the breakdown of acetylcholine which increases the concentration in the synaptic cleft. It is metabolized by the enzymes it inhibits and forms the metabolite NAP226-90.
|
Creator: Selena Created On: August 15, 2023 at 18:47 Last Updated: August 15, 2023 at 18:47 |
PW145087View Pathway |
drug action
Rivastigmine Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 15:03 Last Updated: October 07, 2023 at 15:03 |
PW176230View Pathway |
Rivastigmine Predicted Metabolism PathwayHomo sapiens
Metabolites of Rivastigmine are predicted with biotransformer.
|
Creator: Omolola Created On: December 04, 2023 at 12:58 Last Updated: December 04, 2023 at 12:58 |
PW145052View Pathway |
drug action
Rizatriptan Drug Metabolism Action PathwayHomo sapiens
|
Creator: Ray Kruger Created On: October 07, 2023 at 14:59 Last Updated: October 07, 2023 at 14:59 |